Previous treatment with investigational gene or cell therapy medicine products

Active hepatitis B , hepatitis C or HIV infection

Uncontrolled active infection

Presence of grade 2-4 acute or extensive chronic GVHD

Any uncontrolled active medical disorder that would preclude participation as outlined.

Received non-diagnostic purposes major surgery within the past 4 weeks

Participated in any other clinical study within the past 4 weeks

Used murine biological products (except blinatumomab), unless it is proved no anti-mouse antibodies exist.

Pregnancy or breast-feeding women

Use of prohibited drugs:

Steroids: Therapeutic doses of steroids must be stopped \> 72 hours prior to CD19-CAR-T2 Cells infusion

Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed \> 4 weeks prior to CD19-CAR-T2 Cells infusion

GVHD therapies: Any drug used for GVHD must be stopped \> 4 weeks prior to CD19-CAR-T2 Cells infusion

Any situation that may increase the risk of the test or interfere with the test results

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies